EyePoint Pharmaceuticals (EYPT) Misses Q4 EPS by 14c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q4 EPS of ($0.64), $0.14 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $11.58 million versus the consensus estimate of $10.61 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• PepsiCo (PEP) Misses Q2 EPS by 1c, Beats on Revenue
• Triple Flag posts $129.2M in Q2 2026 revenue, buys back $20M shares
• Expeditors Int'l (EXPD) PT Raised to $191 at UBS